Venclexta (venetoclax)

pCPA File Number: 21564
Negotiation Status:
Under consideration for negotiation
Indication(s):
Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Sponsor/Manufacturer:
AbbVie Corporation
CADTH Project Number:
PC0239-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable